SignatureFD’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.1M | Sell |
1,756
-239
| -12% | -$163K | 0.01% | 409 |
|
|
2026
Q1 | $1.54M | Buy |
1,995
+187
| +10% | +$143K | 0.02% | 295 |
|
|
2025
Q4 | $1.4M | Buy |
1,808
+148
| +9% | +$101K | 0.02% | 302 |
|
|
2025
Q3 | $933K | Sell |
1,660
-98
| -6% | -$55.4K | 0.01% | 399 |
|
|
2025
Q2 | $923K | Sell |
1,758
-383
| -18% | -$214K | 0.02% | 371 |
|
|
2025
Q1 | $1.36M | Buy |
2,141
+113
| +6% | +$77.7K | 0.03% | 262 |
|
|
2024
Q4 | $1.44M | Sell |
2,028
-337
| -14% | -$283K | 0.03% | 231 |
|
|
2024
Q3 | $2.49M | Buy |
2,365
+23
| +1% | +$25.6K | 0.05% | 144 |
|
|
2024
Q2 | $2.46M | Buy |
2,342
+92
| +4% | +$89.2K | 0.05% | 135 |
|
|
2024
Q1 | $2.17M | Buy |
2,250
+124
| +6% | +$118K | 0.05% | 154 |
|
|
2023
Q4 | $1.87M | Buy |
2,126
+54
| +3% | +$44.5K | 0.04% | 167 |
|
|
2023
Q3 | $1.71M | Buy |
2,072
+156
| +8% | +$123K | 0.04% | 157 |
|
|
2023
Q2 | $1.38M | Sell |
1,916
-71
| -4% | -$54.7K | 0.04% | 194 |
|
|
2023
Q1 | $1.63M | Buy |
1,987
+125
| +7% | +$94.3K | 0.04% | 151 |
|
|
2022
Q4 | $1.34M | Buy |
1,862
+93
| +5% | +$68.6K | 0.04% | 173 |
|
|
2022
Q3 | $1.22M | Buy |
1,769
+248
| +16% | +$156K | 0.04% | 152 |
|
|
2022
Q2 | $899K | Sell |
1,521
-163
| -10% | -$106K | 0.03% | 214 |
|
|
2022
Q1 | $1.18M | Buy |
1,684
+149
| +10% | +$94.3K | 0.04% | 185 |
|
|
2021
Q4 | $969K | Buy |
1,535
+214
| +16% | +$132K | 0.03% | 220 |
|
|
2021
Q3 | $799K | Buy |
1,321
+152
| +13% | +$94.4K | 0.03% | 239 |
|
|
2021
Q2 | $653K | Buy |
1,169
+437
| +60% | +$221K | 0.03% | 277 |
|
|
2021
Q1 | $346K | Sell |
732
-177
| -19% | -$86.2K | 0.02% | 403 |
|
|
2020
Q4 | $439K | Buy |
909
+46
| +5% | +$24.8K | 0.02% | 299 |
|
|
2020
Q3 | $483K | Buy |
863
+46
| +6% | +$27.9K | 0.03% | 242 |
|
|
2020
Q2 | $510K | Buy |
817
+246
| +43% | +$140K | 0.03% | 213 |
|
|
2020
Q1 | $279K | Buy |
571
+282
| +98% | +$116K | 0.02% | 316 |
|
|
2019
Q4 | $109K | Buy |
289
+85
| +42% | +$28.6K | 0.01% | 670 |
|
|
2019
Q3 | $57K | Sell |
204
-80
| -28% | -$23.7K | ﹤0.01% | 867 |
|
|
2019
Q2 | $89K | Sell |
284
-201
| -41% | -$66.9K | 0.01% | 673 |
|
|
2019
Q1 | $199K | Sell |
485
-531
| -52% | -$219K | 0.02% | 392 |
|
|
2018
Q4 | $379K | Buy |
1,016
+131
| +15% | +$47.9K | 0.04% | 207 |
|
|
2018
Q3 | $358K | Buy |
885
+527
| +147% | +$201K | 0.04% | 268 |
|
|
2018
Q2 | $124K | Buy |
358
+198
| +124% | +$61.9K | 0.01% | 540 |
|
|
2018
Q1 | $55K | Buy |
+160
| New | +$55.6K | 0.01% | 706 |
|
|
2016
Q4 | – | Sell |
-77
| Closed | -$31K | – | 983 |
|
|
2016
Q3 | $31K | Buy |
77
+5
| +7% | +$2.01K | ﹤0.01% | 671 |
|
|
2016
Q2 | $25K | Buy |
72
+6
| +9% | +$2.31K | ﹤0.01% | 662 |
|
|
2016
Q1 | $24K | Buy |
66
+15
| +29% | +$6.18K | ﹤0.01% | 615 |
|
|
2015
Q4 | $28K | Buy |
51
+21
| +70% | +$11.4K | 0.01% | 495 |
|
|
2015
Q3 | $14K | Buy |
30
+26
| +650% | +$14K | ﹤0.01% | 611 |
|
|
2015
Q2 | $2K | Buy |
+4
| New | +$1.95K | ﹤0.01% | 898 |
|
Other funds holding REGN
SignatureFD's REGN Position: Q2 2026 in Review
SignatureFD reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $163K and leaving 1,756 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #409.
SignatureFD first reported a position in REGN in Q2 2015 and has held it in 40 quarters since. The position peaked at $2.49M in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- SignatureFD held 1,756 shares of Regeneron Pharmaceuticals worth $1.1M as of Q2 2026.
- SignatureFD sold 239 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $163K.
- Regeneron Pharmaceuticals made up 0.01% of SignatureFD's portfolio in Q2 2026, its #409 holding.
- SignatureFD first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
- SignatureFD's Regeneron Pharmaceuticals position peaked at $2.49M in Q3 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.